FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891132859> ?p ?o ?g. }

• W2891132859 endingPage "585" @default.
• W2891132859 startingPage "577" @default.
• W2891132859 abstract "Background: Numerous agents have been trialed following coronary artery bypass grafting (CABG) to maintain long-term graft patency. While clear evidence exists for the use of aspirin in maintaining graft patency, the role of dual-antiplatelet therapy in CABG patients is not as well established. This network meta-analysis aimed to compare the short-term post-CABG graft patency outcomes for patients with none, one or two antiplatelet agents. Methods: Electronic databases were queried for randomized controlled trials comparing CABG graft patency rates at three months and beyond using various antiplatelet agents or placebo. Drug and graft patency data were compared using a mixed treatment comparison under a Bayesian hierarchical framework. A random-effects consistency model was applied. Direct and indirect comparisons were made between drugs and used to determine the relative efficacy for graft patency. Results: The literature search identified 16 papers fulfilling the inclusion criteria, including a total of 3,133 patients with an average of 2.43 [95% confidence interval (CI): 2.20–2.66] grafts per patient. Graft types were incompletely reported, however, saphenous vein grafts (SVGs) were predominantly used [where specifically reported: 4,490 SVG, 1,226 internal mammary artery (IMA) grafts]. In all, five different agents and placebo in various regimens were compared by results of angiographic follow-up conducted at a mean of 10.4 months (95% CI: 9.28–11.5 months). Compared to placebo, aspirin alone [odds ratio (OR) 1.9; 95% credible interval (CrI): 1.3–2.8], aspirin + dipyridamole (OR 1.9; 95% CrI: 1.3–2.6), aspirin + clopidogrel (OR 2.9; 95% CrI: 1.5–5.7) and aspirin + ticagrelor (OR 3.8; 95% CrI: 1.2–13.0) significantly improved graft patency. When compared to aspirin monotherapy, aspirin + clopidogrel (OR 1.6; 95% CrI: 0.86–2.7) and aspirin + ticagrelor (OR 2.0; 95% CrI: 0.69–6.3) had OR that suggested a trend favoring patency compared to aspirin monotherapy, however, these results did not reach significance. Sub-group analysis of SVG graft patency was unable to reach significance (only eight studies with six treatment comparisons were evaluated). Secondary endpoints of death, bleeding, myocardial infarction and cerebrovascular accident were incompletely reported and were pooled but not compared between drug treatment arms. Conclusions: Aspirin monotherapy and dual antiplatelet therapy (DAPT) provided significant all-graft patency benefit compared to placebo at three months and beyond. A trend existed for DAPT to improve graft patency compared to aspirin, although this did not reach statistical significance. Further randomized controlled studies comparing aspirin monotherapy to DAPT are required to determine the utility of DAPT in CABG patients for maintaining graft patency." @default.
• W2891132859 created "2018-09-27" @default.
• W2891132859 creator A5008485582 @default.
• W2891132859 creator A5025436555 @default.
• W2891132859 creator A5026801437 @default.
• W2891132859 creator A5033468770 @default.
• W2891132859 creator A5041216634 @default.
• W2891132859 date "2018-09-01" @default.
• W2891132859 modified "2023-10-14" @default.
• W2891132859 title "Network meta-analysis of antiplatelet therapy following coronary artery bypass grafting (CABG): none versus one versus two antiplatelet agents" @default.
• W2891132859 cites W111766519 @default.
• W2891132859 cites W151402309 @default.
• W2891132859 cites W1537972189 @default.
• W2891132859 cites W1557800596 @default.
• W2891132859 cites W1910901462 @default.
• W2891132859 cites W1964279284 @default.
• W2891132859 cites W1968110297 @default.
• W2891132859 cites W1968278735 @default.
• W2891132859 cites W1971952644 @default.
• W2891132859 cites W1974323708 @default.
• W2891132859 cites W2002636327 @default.
• W2891132859 cites W2004925697 @default.
• W2891132859 cites W2007563349 @default.
• W2891132859 cites W2011206788 @default.
• W2891132859 cites W2011568736 @default.
• W2891132859 cites W2030789648 @default.
• W2891132859 cites W2051299471 @default.
• W2891132859 cites W2056905964 @default.
• W2891132859 cites W2084726831 @default.
• W2891132859 cites W2108696783 @default.
• W2891132859 cites W2115824015 @default.
• W2891132859 cites W2117950068 @default.
• W2891132859 cites W2148737731 @default.
• W2891132859 cites W2161817962 @default.
• W2891132859 cites W2163764554 @default.
• W2891132859 cites W2170892587 @default.
• W2891132859 cites W2258946945 @default.
• W2891132859 cites W2259805593 @default.
• W2891132859 cites W2270450228 @default.
• W2891132859 cites W2331820709 @default.
• W2891132859 cites W2336744020 @default.
• W2891132859 cites W2590234387 @default.
• W2891132859 cites W2766874789 @default.
• W2891132859 cites W2771718566 @default.
• W2891132859 cites W60541414 @default.
• W2891132859 cites W85630666 @default.
• W2891132859 doi "https://doi.org/10.21037/acs.2018.09.02" @default.
• W2891132859 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6219956" @default.
• W2891132859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30505741" @default.
• W2891132859 hasPublicationYear "2018" @default.
• W2891132859 type Work @default.
• W2891132859 sameAs 2891132859 @default.
• W2891132859 citedByCount "19" @default.
• W2891132859 countsByYear W28911328592019 @default.
• W2891132859 countsByYear W28911328592020 @default.
• W2891132859 countsByYear W28911328592021 @default.
• W2891132859 countsByYear W28911328592022 @default.
• W2891132859 countsByYear W28911328592023 @default.
• W2891132859 crossrefType "journal-article" @default.
• W2891132859 hasAuthorship W2891132859A5008485582 @default.
• W2891132859 hasAuthorship W2891132859A5025436555 @default.
• W2891132859 hasAuthorship W2891132859A5026801437 @default.
• W2891132859 hasAuthorship W2891132859A5033468770 @default.
• W2891132859 hasAuthorship W2891132859A5041216634 @default.
• W2891132859 hasBestOaLocation W28911328591 @default.
• W2891132859 hasConcept C126322002 @default.
• W2891132859 hasConcept C141071460 @default.
• W2891132859 hasConcept C142724271 @default.
• W2891132859 hasConcept C156957248 @default.
• W2891132859 hasConcept C164705383 @default.
• W2891132859 hasConcept C168563851 @default.
• W2891132859 hasConcept C204787440 @default.
• W2891132859 hasConcept C27081682 @default.
• W2891132859 hasConcept C2776820930 @default.
• W2891132859 hasConcept C2776890861 @default.
• W2891132859 hasConcept C2777628954 @default.
• W2891132859 hasConcept C2909112448 @default.
• W2891132859 hasConcept C44249647 @default.
• W2891132859 hasConcept C71924100 @default.
• W2891132859 hasConceptScore W2891132859C126322002 @default.
• W2891132859 hasConceptScore W2891132859C141071460 @default.
• W2891132859 hasConceptScore W2891132859C142724271 @default.
• W2891132859 hasConceptScore W2891132859C156957248 @default.
• W2891132859 hasConceptScore W2891132859C164705383 @default.
• W2891132859 hasConceptScore W2891132859C168563851 @default.
• W2891132859 hasConceptScore W2891132859C204787440 @default.
• W2891132859 hasConceptScore W2891132859C27081682 @default.
• W2891132859 hasConceptScore W2891132859C2776820930 @default.
• W2891132859 hasConceptScore W2891132859C2776890861 @default.
• W2891132859 hasConceptScore W2891132859C2777628954 @default.
• W2891132859 hasConceptScore W2891132859C2909112448 @default.
• W2891132859 hasConceptScore W2891132859C44249647 @default.
• W2891132859 hasConceptScore W2891132859C71924100 @default.
• W2891132859 hasIssue "5" @default.
• W2891132859 hasLocation W28911328591 @default.
• W2891132859 hasLocation W28911328592 @default.
• W2891132859 hasLocation W28911328593 @default.
• W2891132859 hasLocation W28911328594 @default.

• next